GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] we are measuring EU at the wrong time and calling it noise — 13 comments in the full submission. View in context.
150
c/glp1eu·submitted 7 months ago by u/milan_mensah

[Discussion] we are measuring EU at the wrong time and calling it noise

Discussionbranch of 7 comments

Long-ish post, sorry. tl;dr at the bottom. I have been tracking EU against triglycerides for 15 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…

Read the full submission and all 13 comments →

This branch

7 comments, started 7 months ago
u/zaid_eriksen14 points·7 months ago

Mechanistically the bit that matters is reimbursement. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/milan_mensahOP7 points·7 months ago

the the Netherlands answer is not the the Netherlands answer

replysharereportpermalink
u/milan_mensahOP4 points·7 months ago

EU rules is usually a national question wearing a hat

replysharereportpermalink
u/milan_mensahOP2 points·7 months ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/tuva_aalto1 point·7 months ago·edited

reimbursement costs in the UK this month

replysharereportpermalink
u/cato_batista1 point·7 months ago

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

replysharereportpermalink
u/noor_ivaturi1 point·7 months ago

private and public prescription routes differ

replysharereportpermalink

← back to the whole thread

About c/glp1eu

European access, country by country: prescription routes, reimbursement reality, pharmacy stock, EMA notices and the fact that "EU rules" is usually a national question wearing a European hat.

32kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1eu rules
  1. Tag your country in the title. Bare "EU" questions get a template reply.
  2. Pricing posts need the date and the currency.
  3. EMA and national agency claims need a citation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.